We found that TalaA blocked the transition from the G1 to S phase of bladder cancer cells and downregulated CCNA2 and CCNB1, which are well-known therapeutic targets for various cancers (11, 12, 13). The gene discussed is CCNB1; the disease is urinary bladder carcinoma.